Tuberous sclerosis complex; a single center experience

dc.contributor.authorErol, Ilknur
dc.contributor.authorSavas, Tulin
dc.contributor.authorSekerci, Sevda
dc.contributor.authorYazici, Nalan
dc.contributor.authorErbay, Ayse
dc.contributor.authorDemir, Senay
dc.contributor.authorSaygi, Semra
dc.contributor.authorAlkan, Ozlem
dc.contributor.pubmedID26078697en_US
dc.date.accessioned2019-12-06T13:32:10Z
dc.date.available2019-12-06T13:32:10Z
dc.date.issued2015
dc.description.abstractAim: This study was planned with the aim of retrospectively reviewing the clinical and laboratory findings and therapies of our patients diagnosed with tuberous sclerosis and redefining the patients according to the diagnostic criteria revised by the 2012 International Tuberous Sclerosis Complex Consensus Group and comparing them with the literature. Material and Methods: 20 patients diagnosed with tuberous sclerosis complex in the Pediatric Neurology Clinic were examined retrospectively in terms of clinical findings and therapies. The diagnoses were compared again according to 1998 and 2012 criteria. Results: It was observed that the complaint at presentation was seizure in 17 of 20 patients and hypopigmented spots on the skin in 3 of 20 patients. On the initial physical examination, imaging findings related with the disease were found in the skin in 17 of the patients, in the eye in 5, in the kidneys in 7 and in the brain in 17. No cardiac involvement was observed in the patients. Infantile spasm was observed in 7 of the patients who presented because of seizure (n=17), partial seizure was observed in 7 and multiple seizure types were observed in 3. It was found that sirolimus treatment was given to 9 of 20 patients because of different reasons, 7 of these 9 patients had epileptic seizures and sirolimus treatment had no effect on epileptic seizures. According to 2012 diagnostic criteria, no marked change occured in the diagnoses of our patients. Conclusions: It was observed that the signs and symptoms of our patients were compatible with the literature. Molecular genetic examination was planned for the patients who were being followed up because of possible tuberous sclerosis complex. It was observed that sirolimus treatment had no marked effect on the seizure frequency of our patients.en_US
dc.identifier.endpage60en_US
dc.identifier.issn1306-0015
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84926635129en_US
dc.identifier.startpage51en_US
dc.identifier.urihttps://www.journalagent.com/tpa/pdfs/TPA_50_1_51_60.pdf
dc.identifier.urihttp://hdl.handle.net/11727/4368
dc.identifier.volume50en_US
dc.identifier.wos000359058400008en_US
dc.language.isoturen_US
dc.relation.isversionof10.5152/tpa.2015.2138en_US
dc.relation.journalTURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiagnostic criteriaen_US
dc.subjectmammalian target of rapamycin (mTOR)en_US
dc.subjecttuberous sclerosis complexen_US
dc.titleTuberous sclerosis complex; a single center experienceen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
TPA_50_1_51_60.pdf
Size:
180.4 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: